-transparent.png){kind=logo}
Immune functions, including cell surface markers, interleukin-2 receptor levels and responses of lymphocytes to mitogenic stimulation were evaluated in seven growth hormone deficient children ages 4-15 years, during treatment with biosynthetically derived human growth hormone. Treatment resulted in a decrease in % B cells and in % T total cells and also decreases in most individual patients' mitogen responses and interleukin-2 receptor levels. Most of the changes noted were transient and similar to those previously demonstrated during pituitary-derived human growth hormone treatment. Although not resulting in overt clinical manifestations in our patients, we think that potential interactions between growth hormone and immune functions need to be considered by physicians treating children with growth hormone.
R Rapaport, and
B Petersen, and
K A Skuza, and
M Heim, and
S Goldstein
January 1988,
Acta paediatrica Scandinavica,
R Rapaport, and
B Petersen, and
K A Skuza, and
M Heim, and
S Goldstein
January 1991,
Acta paediatrica Scandinavica,
R Rapaport, and
B Petersen, and
K A Skuza, and
M Heim, and
S Goldstein
September 1989,
The Journal of pediatrics,
R Rapaport, and
B Petersen, and
K A Skuza, and
M Heim, and
S Goldstein
September 1986,
The Journal of pediatrics,
R Rapaport, and
B Petersen, and
K A Skuza, and
M Heim, and
S Goldstein
January 1995,
Clinical endocrinology,
R Rapaport, and
B Petersen, and
K A Skuza, and
M Heim, and
S Goldstein
January 1991,
Hormone research,
R Rapaport, and
B Petersen, and
K A Skuza, and
M Heim, and
S Goldstein
May 1988,
Acta endocrinologica,
R Rapaport, and
B Petersen, and
K A Skuza, and
M Heim, and
S Goldstein
January 1987,
Srpski arhiv za celokupno lekarstvo,
R Rapaport, and
B Petersen, and
K A Skuza, and
M Heim, and
S Goldstein
November 1987,
Life sciences,
R Rapaport, and
B Petersen, and
K A Skuza, and
M Heim, and
S Goldstein
May 1991,
Clinical endocrinology,
